孙药和Philogen签署了针对抗癌免疫疗法Fibromun的全球许可协议,增强了孙药的瘤组合. Sun Pharma and Philogen sign global licensing agreement for anti-cancer immunotherapy Fibromun, enhancing Sun Pharma's oncology portfolio.
太阳制药工业和Philogen S.p.A.已经签署了关于Fibromun的全球许可证协议,这是针对软组织沙眼和血浆瘤的抗癌症免疫疗法。 Sun Pharmaceutical Industries and Philogen S.p.A. have signed a global licensing agreement for Fibromun, an anti-cancer immunotherapy targeting soft tissue sarcoma and glioblastoma. SunPharma公司获得了全世界独家的商业化权利,而Philogen公司将进行持续的临床试验,并寻求监管批准。 Sun Pharma gains exclusive worldwide commercialization rights, while Philogen will conduct ongoing clinical trials and pursue regulatory approval. Philogen 的收入分成设定为 45%，Sun Pharma 设定为 55%。 Revenue sharing is set at 45% for Philogen and 55% for Sun Pharma. 这一伙伴关系加强了太阳药厂的肿瘤组合。 This partnership enhances Sun Pharma's oncology portfolio.